Jesi

This research aims to evaluate how well guselkumab works in improving symptoms of psoriatic arthritis, an inflammatory joint disease affecting people with psoriasis, a skin condition that causes red, scaly patches. The study uses musculoskeletal ultrasound (MSUS) to assess treatment effects in a real-world clinical setting, focusing on participants with active psoriatic arthritis based on specific clinical and imaging criteria. Participants will start guselkumab treatment as part of their standard clinical care either at enrollment or within two weeks after the initial visit. Eligible participants are either biologic-naïve or have previously used only one biologic disease-modifying antirheumatic drug (bDMARD) or apremilast/deucravacitinib. The study includes detailed ultrasound assessments of joint inflammation and enthesitis (inflammation where tendons or ligaments attach to bone) before starting guselkumab. Throughout the study, researchers will monitor changes in joint inflammation using ultrasound scores at baseline and week 12, and evaluate disease activity using standardized disease activity indices at week 24. Participants will undergo clinical assessments, imaging, and laboratory tests related to psoriatic arthritis activity. The goal is to measure how guselkumab affects inflammation and disease activity over time in a real-world patient population.

Researchers are evaluating patients who have experienced athero-thrombotic events such as coronary artery disease, cerebrovascular disease, or peripheral artery disease. The study aims to assess how well patients follow guideline recommendations, particularly focusing on improving cholesterol levels and other modifiable risk factors to reduce the chance of cardiovascular event recurrence. This observational and prospective study takes place across multiple cardiology centers in Italy to represent a broad patient population. The study includes several phases starting with an educational intervention to discuss guideline recommendations for secondary prevention. Following this, data is collected for three months or until 30 patients with documented cardiovascular conditions are enrolled, using a web-based case record form that identifies when guidelines are not followed and records reasons for non-adherence. After six months, primary and secondary outcomes are evaluated. A second educational intervention then shares findings from the first phase to highlight gaps in clinical practice, followed by another three-month data collection period and a further six-month outcome assessment. Finally, all patients are followed for 12 months to monitor longer-term results. Participants provide informed consent and are monitored through data collection forms that track adherence to guidelines and clinical outcomes. The main outcome measured is adherence to cholesterol management guidelines over six months. Additional assessments include adherence to recommendations for other cardiovascular risk factors. Throughout the study, researchers gather data to understand how guideline adherence affects patient health and to identify barriers to following best practices, with continuous follow-up over a year to evaluate sustained effects.

Researchers are evaluating the impact of a mobile health (m-health) solution on improving the self-management skills of adults with Type 2 Diabetes Mellitus (T2DM) living in the Marche region of Italy. This randomized clinical trial compares the personalized m-health solution, integrated with patients' Electronic Patient Records (EPR), to usual care. The main goal is to assess changes in glycated haemoglobin (HbA1c) levels from the start of the intervention through 18 months, along with other health-related factors like medication adherence, lifestyle habits, self-efficacy, and quality of life. Participants in the treated group will receive training and personalized setup of the m-health solution, which includes mobile applications for tracking health data, receiving alerts and motivational messages, communicating with healthcare professionals, and accessing educational materials. Healthcare providers at Diabetes Centres (CADs) will monitor patient data via a dedicated EPR interface and maintain communication as needed. The intervention begins at the CADs and continues at participants' homes, with follow-up evaluations at 6, 12, and 18 months. Throughout the study, participants will complete self-administered questionnaires and clinical assessments during routine physician visits. Data will be collected from the m-health solution, clinical evaluations, and focus groups to evaluate usability, patient experience, and cost-effectiveness. Importantly, no extra visits or laboratory tests beyond usual care are required. The total observation period spans 18 months from baseline to final follow-up.

Obstructive Sleep Apnea (OSA) is a common sleep-related breathing disorder linked to serious health risks like cardiovascular, cerebrovascular, and metabolic diseases. This research focuses on understanding OSA in the Italian population, as previous European studies showed varied symptoms and complications but lacked detailed data specific to Italy. The study aims to assess different physiological and clinical patterns of OSA in Italian patients, explore its association with other health conditions, and establish a long-term database for follow-up and prevention efforts. Participants suspected of having OSA will undergo polysomnography, a sleep study to confirm the diagnosis. Clinical data, sleep study results, and treatment information will be collected using a standardized clinical questionnaire. Additional tests may include EKG, spirometry, blood pressure monitoring, blood chemistry, and assessments of vitamin levels and glycemic control. The study will also screen for excessive daytime sleepiness, cognitive function, and anxiety or depression using established questionnaires. Throughout the study, data will be gathered and stored on a secure web-based platform. Researchers will analyze OSA severity, associated metabolic and cardiovascular risk factors, and the distribution of different OSA patterns. The study will create a registry to support future prevention and early diagnosis programs within the Italian Health System. Participants must be 18 or older and suspected of OSA, with safety monitoring ensuring those with unstable psychiatric conditions or limited life expectancy are excluded.